Compare TWI & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TWI | LRMR |
|---|---|---|
| Founded | 1890 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 494.4M | 455.8M |
| IPO Year | 1997 | 2014 |
| Metric | TWI | LRMR |
|---|---|---|
| Price | $7.17 | $3.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $12.00 | ★ $16.50 |
| AVG Volume (30 Days) | 411.8K | ★ 1.7M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.69 | N/A |
| Revenue Next Year | $4.85 | $1,816.14 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.43 | $2.26 |
| 52 Week High | $11.70 | $6.42 |
| Indicator | TWI | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 42.65 | 31.98 |
| Support Level | $7.20 | $3.10 |
| Resistance Level | $8.38 | $3.74 |
| Average True Range (ATR) | 0.30 | 0.19 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 24.86 | 3.64 |
Titan International Inc is a manufacturer of wheels, tires, wheel and tire assemblies, and undercarriage systems and components for off-highway vehicles. It designs and manufactures products for OEMs and aftermarket customers in the agricultural, earthmoving/construction, and consumer markets. The company operates through three segments, namely Agricultural, Earthmoving/Construction, and Consumer. It derives the majority of revenue from the Agricultural segment which manufactures various agricultural equipment, including tractors, combines, plows, planters and irrigation equipment. Geographically, the company generates the maximum revenue from North America, followed by Europe / CIS, Latin America, and Asia and other regions.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.